19 separate 3- to 5-day ultrafiltration peritoneal dialyses (UPD) were performed in 12 markedly edematous patients. A 7-percent dextrose dialysis solution with 120 mEq/l sodium (7–120) was used in 10 dialyses and 4.5% dextrose with 130 mEq/l sodium (4.5–130) in 9 dialyses. Each exchange was cycled every 2 h. Daily negative balance of 3–41 was achieved. Predialysis and postdialysis serum sodium concentration was 136 ± 7 mEq/l (mean ± l SD), 135 ± 5 with 7–120 and 139 ± 7, 137 ± 4 with 4.5–130. Predialysis and postdialysis serum chloride was 103 ± 6mEq/l, 106 ± 9 with 7–120 and 108 ± 6, 108 ± 5 with 4.5–130. The ratio of sodium concentration in ultra-filtrate to the serum sodium (SCNa) was 0.92 ± 0.13 with 7–120 and 0.96 ± 0.12 with 4.5–130. There was a positive correlation between serum sodium and SCNa and a negative correlation between ultrafiltration volume and SCNa with both the solutions. No clinical complications were noted. The data suggest that hypernatremia is avoided in UPD with 7–120 and 4.5–130 with 2-hour exchange. The exclusive use of these solutions is relatively safe and does not result in hyponatremia during UPD in edematous patients.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.